SCHEMBL771478

SCHEMBL771478

C[C@@H]1CN(C(=O)C(=O)N2CCC3CCCC=C3C2)C[C@H](C)O1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.38
PKM P14618 1/20 0.38
MAPK1 P28482 1/20 0.38
HPGD P15428 5/20 0.36
KMT2A Q03164 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KDM4E B2RXH2 2/20 0.36
NPC1 O15118 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TSHR P16473 1/20 0.35
RAB9A P51151 1/20 0.35
MEN1 O00255 1/20 0.34
CYP2C19 P33261 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770238 0.86 ALDH1A1 (0.42) ALDH1A1HPGDKMT2ASMN1; SMN2KDM4E
SCHEMBL769770 0.86 ALDH1A1 (0.40) ALDH1A1HPGDKMT2ASMN1; SMN2KDM4E
SCHEMBL772492 0.86 L3MBTL3 (0.33) ALDH1A1HPGDSMN1; SMN2NPC1RAB9A
SCHEMBL769878 0.86 KMT2A (0.36) ALDH1A1HPGDKMT2ASMN1; SMN2KDM4E
SCHEMBL771318 0.84 ALDH1A1 (0.41) ALDH1A1HPGDKMT2ASMN1; SMN2KDM4E
SCHEMBL770485 0.84 ACHE (0.38) ALDH1A1HPGDKMT2ASMN1; SMN2NPC1
SCHEMBL771057 0.82 RECQL (0.42) ALDH1A1MAPK1HPGDKMT2ASMN1; SMN2
SCHEMBL770905 0.81 ALDH1A1 (0.36) ALDH1A1HPGDKMT2AKDM4EMEN1
SCHEMBL770413 0.81 RBP4 (0.38) ALDH1A1HPGDSMN1; SMN2NPC1RAB9A
SCHEMBL771570 0.80 L3MBTL3 (0.37) ALDH1A1HPGDKMT2ASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 144/4885PKM 1551/4885MAPK1 401/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 142/4885PKM 1554/4885MAPK1 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.